TTOXICOLOGICAL EVALUATION OF COMBINATION OF AMLODIPINE CALCIUM CHANNELS BLOCKER WITH ANGIOTENSIN RECEPTOR BLOCKERS

封面

如何引用文章

全文:

详细

The article summarizes experimental data on toxicological interactions of blocker of amplodipine slow calcium channels with angiotensin II (AT1 subtype) receptors blockers (valsartan and losartan). Toxicity studies were performed in outbred rats after a single intragastric administration in doses permitting to estimate lethal doses for the objects under investigation (amlodipine, valsartan, losartan, amlodipine+ losartan 1:10, amlodipine+ losartan 1:20, amlodipine + valsartan 1:16, amlodipine + valsartan 1:32). Based on the research outcome, the possibility of different types of toxicological interaction is shown between representatives of classes of slow calcium channels blockers and angiotensin II receptors blockers: from potentiation of toxic effects to the antagonism in relation to toxicity. Identified toxicological interactions in fixed combinations depend on the proportion of active ingredients in the combination, as well as on modes of action features and pharmacokinetics of each active ingredient.

作者简介

O. Avdeeva

Saint-Petersburg Institute of Pharmacy

编辑信件的主要联系方式.
Email: noemail@neicon.ru
俄罗斯联邦

M. Makarova

Saint-Petersburg Institute of Pharmacy

Email: noemail@neicon.ru
俄罗斯联邦

I. Makarenko

Saint-Petersburg Institute of Pharmacy

Email: noemail@neicon.ru
俄罗斯联邦

P. Burenkov

Saint-Petersburg Institute of Pharmacy

Email: noemail@neicon.ru
俄罗斯联邦

M. Shubina

Saint-Petersburg Institute of Pharmacy

Email: noemail@neicon.ru
俄罗斯联邦

V. Kashkin

Saint-Petersburg Institute of Pharmacy

Email: noemail@neicon.ru
俄罗斯联邦

参考

  1. Маколкин В.И. Путь к улучшению лечения артериальной гипертонии – комбинированная терапия // РМЖ. 2011. № 2. С.74–77.
  2. Сорокин Е.В., Карпов Ю.А. Комбинированная антигипертензивная терапия – ключ к повышению эффективности сердечно – сосудистой профилактики // Кардиология. РМЖ. 2012. № 25. 1304.
  3. Park C.G. et al. // Am. J. Cardiovasc. Drugs. 2012. V. 12. № 1. P 35.
  4. Чазова И.Е., Мартынюк Т.В. Возможности рациональной комбинированной антигипертензивной терапии: итоги международного клинического исследования ГЕМЕРА // Терапевтический архив. 2013. № 10. С. 10 – 22.
  5. Finney D.J. A statistical treatment of the sigmoid response curves/ Probit analysis. 2nd ed. Cambridge. Univ. Press. 1952. Р. 131–140.
  6. MSDS Caduet (Amlodipine besylate/ Atorvastatin calcium) tablets-5 mg/10 mg and 10 mg/20 mg [http://www.pfizer.com/files/products/ material_safety_data/PZ01099.pdf], электронный ресурс, дата обращения 24.10.2013.
  7. MSDS Losartan Potassium Tablets [http://www.pfizer.com/files/products/ material_safety_data/PZ01099.pdf], электронный ресурс, дата обращения 24.10.2013.
  8. MSDS и ЛД50 Валсартан. Электронный ресурс: http://www.usp.org/pdf/EN/ referenceStandards/msds/1708762.pdf. Дата обращения 11.2014 г.
  9. Kim K. A., Park P. W., Park J. Y. Effect of cytochrome P450 3A5* 3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects //Chirality. 2009. Т. 21. №. 5. С. 485-491.
  10. Beresford A. P., Macrae P. V., Stopher D. A. Metabolism of amlodipine in the rat and the dog: a species difference //Xenobiotica. 1988. Т. 18. №. 2. С. 169-182.
  11. Nakashima A. et al. Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes //Xenobiotica. 2005. Т. 35. №. 6. С. 589-602.
  12. Stearns R. A. et al. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members //Drug metabolism and disposition. 1995. Т. 23. №. 2. С. 207-215.
  13. Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans // Clin Pharmacol Ther. 1995; V.58(6) p.641-9.
  14. Yun C. H. et al. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A (4) in formation of the active metabolite EXP3174 //Drug metabolism and disposition. 1995. Т. 23. №. 2. С. 285-289.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Avdeeva O.I., Makarova M.N., Makarenko I.E., Burenkov P.V., Shubina M.G., Kashkin V.A., 2016


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 81728 от 11 декабря 2013.